Recent news from 24dunia
   

Search results for  

Ranbaxy s Sobti s Friday Gurgaon to hit stands by monthend 

 ( 1-10 )
Sort by: Relevance |   Date
 

FDA approves Ranbaxy's Gurgaon & Romania centres

Pharmaceutical Industries gained 3.7% to Rs 609 at 09:46 IST on BSE, with the stock extending Monday's gain triggered by plans to acquire 100% of Ranbaxy Laboratories in an all-stock transaction.This move came after the Gurgaon-headquartered drugmaker was hit by several strictures last yearReport stated that Units of Ranbaxy's R&D centre at Gurgaon and its clinical research centre related to bioeq...
Source : Indiainfoline |
Category : Business

One killed in Gurgaon expressway accident

person was killed and at least five injured Friday after a speeding truck hit a cab on the Delhi-Gurgaon expressway,...
Source : Webindia123 |
Category : Headlines

3.00 Bedrooms Residential Bungalow/House in Air Force Gurgaon Gurgaon, India

Sector-12A Gurgaon Main Road Location Park Facing walking distance to main bus stand...
Source : India Properties |
Category : Others | City : Udham Singh Nagar

Sun bid to clear air on drug deal

Pharma today denied insider trading allegations against its wholly owned arm Silverstreet Developers LLP in the $3.2-billion acquisition of Ranbaxy Laboratories.Silverstreet Developers, which had no holding in Ranbaxy till September last year, had bought shares of the Gurgaon-based company aggregating 1.41 per cent stake by the end of December. As on March 31 this year, its holding stood at 1.64 per...
Source : Telegraphindia |
Category : Business | City : Mon

India's Ranbaxy faces more regulatory scrutiny after U.S. ban

rides a motorcycle in front of the office of Ranbaxy Laboratories at Gurgaon, on the outskirts of New Delhi, June 13, 2013.(Reuters) - Ranbaxy Laboratories Ltd has been hit by more regulatory scrutiny sparked by a U.S. ban on the bulk of its drugs, in a backlash that could bump up compliance costs and erode profitability among some Indian makers of generic drugs.India's biggest drugmaker by revenue,...
Source : Reuters India |
Category : Health | City : Mumbai

Third FDA ban on India's Ranbaxy threatens its U.S. sales

man rides a motorcycle in front of the office of Ranbaxy Laboratories at Gurgaon, on the outskirts of New Delhi in this June 13, 2013 file photo.(Reuters) - A third Ranbaxy Laboratories Ltd plant in India has been hit by a U.S. import ban over quality concerns, dealing a blow to the company's turnaround plans and threatening to hurt new launches and sales of medicines to its largest market.With the...
Source : Reuters India |
Category : Health

Ranbaxy to implement Instem's Provantis preclinical software suite at Gurgaon R&D center in India

Instem, a leading provider of IT solutions to the global early development healthcare market, is pleased to announce that Ranbaxy Laboratories Limited (Ranbaxy) has purchased the Provantis® preclinical software suite to automate laboratory processes at their R&D Headquarters in Gurgaon, India.Ranbaxy is a research based international pharmaceutical company serving customers in over 150 countries. Ranbaxy...
Source : news-medical |
Category : Health

Car kills toddler in Gurgaon

Gurgaon, July 11 (IANS) A two-year-old boy was killed when a speeding car hit him and his mother near here Friday, police said.The mother and child were hit by an unidentified car in Pahri village near Pataudi Friday morning, some 35 km from Gurgaon."Deceased Shivam was adopted by the couple (Dayachand and Maya) a few months back from Dayachand's younger sister," police officer Prahlad Singh told ...
Source : Chennaionline |
Category : Headlines | City : Chennai

Ranbaxy hit by FDA product ban at fourth Indian plant; stock slumps 19 pct

rides a motorcycle in front of the office of Ranbaxy Laboratories at Gurgaon, on the outskirts of New Delhi, June 13, 2013. REUTERS/Adnan Abidi/FilesREUTERS - The U.S. Food and Drug Administration has banned products from a fourth plant run by Indian drugmaker Ranbaxy Laboratories(NSI:) from entering the United States due to manufacturing violations, sending its stock down nearly 20 percent on Friday.The...
Source : Yahoo Finance |
Category : Personal Finance

Ranbaxy whistle-blower says drug maker faked data

general view of the office of Ranbaxy Laboratories is pictured at Gurgaon, on the outskirts of New DelhiAn Indian origin whistle-blower, who exposed a massive fraud by the Indian pharmaceutical giant Ranbaxy, has accused the generic drug maker of faking test results for approval by the US drug regulator.Generic drug companies such as Ranbaxy have to prove their drugs are "bioequivalent", which means...
Source : Ndtv |
Category : Others
Related search
 
 
 
 
 
 
 
 
   
0
|
0
Bookmark and Share